UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) Washington D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission file number: 000-28827 ______________________ FORM 10-Q Securities registered pursuant to Section 12(b) of the Exchange Act: | T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number 000-28827 PETMED EXPRESS, INC. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 (State or other jurisdiction of (IRS Empl ...

PetMed Express, Inc. (NASDAQ:PETS) Q4 2020 Earnings Conference Call May 3, 2021 8:30 AM ET Company Participants Bruce Rosenbloom - Chief Financial Officer and Treasurer Menderes Akdag - President and Chief Executive Officer Conference Call Participants Erin Wright - Credit Suisse AG Anthony Lebiedzinski - Sidoti & Company, LLC Ben Rose - Battle Road Research Ltd. Operator Welcome to the PetMed Express Incorporated doing business as 1-800-PetMeds Conference Call to Review the Financial Results for the Fourth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission file number: 000-28827 ______________________ PETMED EXPRESS, INC. (Exact name of registrant as specified in its c ...

PetMed Express, Inc. (NASDAQ:PETS) Q3 2020 Earnings Conference Call January 19, 2021 8:30 AM ET Company Participants Bruce Rosenbloom - Chief Financial Officer Mendo Akdag - President and Chief Executive Officer Conference Call Participants Erin Wright - Credit Suisse Anthony Lebiedzinski - Sidoti Ben Rose - Battle Road Research Operator Welcome to the PetMed Express Inc., doing business as 1-800-PetMeds Conference Call to review the Financial Results for the Third Fiscal Quarter for the quarter ended on De ...

Financial Data and Key Metrics Changes - For Q2 2020, sales increased to $75.4 million from $69.9 million in Q2 2019, representing a 7.9% increase [10] - Net income rose to $8.4 million or $0.42 diluted per share, compared to $6.7 million or $0.33 diluted per share in the prior year, marking a 26% increase [11] - Gross profit as a percentage of sales improved to 30.5% from 28.6% year-over-year [15] Business Line Data and Key Metrics Changes - Reorder sales increased by 9.6% to $67.8 million for the quarter, while new order sales decreased by 5% to $7.7 million [12][13] - The average order value was approximately $87 for the quarter, up from $85 in the same period last year [10] Market Data and Key Metrics Changes - Consumer demand settled down due to the reopening of vet clinics and pet retailers, along with consumers having stocked up in the previous quarter [8] - The company acquired approximately 96,000 new customers in Q2 2020, slightly down from 98,000 in Q2 2019 [13] Company Strategy and Development Direction - The company is focusing on redesigning its website and mobile app to enhance the digital experience for customers [70] - There is a shift towards higher-margin prescription medications, which now account for more than half of total sales [22][24] Management's Comments on Operating Environment and Future Outlook - Management noted that the demand has settled down with the reopening of clinics and stores, but reorder sales remain strong [28] - The impact of COVID-19 on future demand is uncertain, with management monitoring trends closely [28] Other Important Information - The company had $106.3 million in cash and cash equivalents and $21.5 million in inventory with no debt as of September 30, 2020 [18] - Advertising expenses increased to $5.1 million for the quarter, up from $4.8 million in the same quarter last year [17] Q&A Session Summary Question: What is the mix of over-the-counter versus prescription medications now? - Management indicated that prescription medications have increased and now account for over half of total sales [22][24] Question: How has COVID-19 affected customer behavior? - Management noted a shift in demand due to the reopening of vet clinics and stores, along with a temporary negative impact from the new website platform [26][28] Question: What is the expected completion date for the website improvements? - The target date for the completion of the website redesign is during the third quarter of the fiscal year [33] Question: What is driving the increase in advertising spending? - The increase in advertising spending is attributed to normalized increases in keyword search costs and competition [34] Question: Will gross margins continue to improve in the second half of the year? - Management expects modest year-over-year margin improvements, but noted that margins are assessed on an annual basis rather than quarterly [36][59]

PetMed Express, Inc. (NASDAQ:PETS) Q1 2020 Results Conference Call July 20, 2020 8:30 AM ET Company Participants Bruce Rosenbloom - CFO Mendo Akdag - President and CEO Conference Call Participants Anthony Lebiedzinski - Sidoti & Company Ben Rose - Battle Road Research Kevin Ellich - Ace Research Anthony Lebiedzinski - Sidoti & Company Operator Welcome to the PetMed Express Incorporated doing business as 1800PetMeds Conference Call to review the Financial Results for the First Fiscal Quarter Ended on June 30 ...

PetMed Express, Inc. (NASDAQ:PETS) Q4 2019 Earnings Conference Call May 4, 2020 8:30 AM ET Company Participants Bruce Rosenbloom - Chief Financial Officer Mendo Akdag - President and Chief Executive Officer Conference Call Participants Erin Wright - Credit Suisse Kevin Ellich - Ace Research Anthony Lebiedzinski - Sidoti & Company Ben Rose - Battle Road Research Operator Welcome to the PetMed Express Incorporated doing business as 1800PetMeds Conference Call to Review the financial results for the Fourth Fis ...

PetMed Express, Inc (NASDAQ:PETS) Q3 2019 Earnings Conference Call January 21, 2019 8:30 AM ET Company Participants Bruce Rosenbloom - Chief Financial Officer Mendo Akdag - President and Chief Executive Officer Conference Call Participants Kevin Ellich - Ace Research LLC Anthony Lebiedzinski - Sidoti & Company Operator Welcome to the PetMed Express Incorporated doing business as 1800PetMeds Conference Call to review the financial results for the Third Fiscal Quarter ended December 31, 2019. At the request o ...

PetMed Express, Inc (NASDAQ:PETS) Q2 2019 Earnings Conference Call October 21, 2019 8:30 AM ET Company Participants Bruce Rosenbloom - Chief Financial Officer Mendo Akdag - President and Chief Executive Officer Conference Call Participants Erin Wright - Credit Suisse Kevin Ellich - Craig-Hallum Anthony Lebiedzinski - Sidoti & Company Operator Welcome to the PetMed Express Inc. doing business as 1-800-PetMeds Conference Call to review the financial results for the Second Fiscal Quarter ended last September 3 ...